← Back to Search

Procedure

EBUS-TBNA for Lung Cancer

N/A

Recruiting

Led By Kazuhiro Yasufuku, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Performance status score (WHO/ECOG) of 0-2

Medically inoperable for surgical resection

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial reports that a less invasive but effective treatment, stereotactic body radiation therapy (SBRT), is well-tolerated for early stage lung cancer in medically inoperable patients.

Who is the study for?

This trial is for adults over 18 with confirmed non-small cell lung cancer who can't have surgery or chose not to. They should be in fair health (performance status 0-2), have early-stage T1-2 disease without distant metastasis, and need EBUS-TBNA staging before SBRT treatment. Pregnant women, those unfit for bronchoscopy, or planning other treatments are excluded.Check my eligibility

What is being tested?

The trial tests the use of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) for lymph node staging in patients with lung cancer who will undergo Stereotactic Body Radiotherapy (SBRT). It aims to provide a less invasive option for accurate diagnosis and treatment planning.See study design

What are the potential side effects?

While specific side effects aren't listed here, EBUS-TBNA is generally considered minimally invasive with potential risks like minor bleeding, infection risk at the needle site, and discomfort similar to other bronchoscopy procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and am up and about more than 50% of my waking hours.

Select...

I cannot undergo surgery for my condition.

Select...

I am 18 years old or older.

Select...

My cancer is confirmed as non-small cell lung cancer through testing.

Select...

My cancer is in an early stage and hasn't spread far.

Select...

I have chosen not to undergo surgery for my condition.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To test whether or not there is a difference in accuracy between CT/PET and the minimally invasive technique of EBUS-TBNA for mediastinal staging in patients with non-small cell lung cancer prior to stereotactic body radiotherapy (SBRT).

Secondary outcome measures

The treatment outcome (nodal recurrence rate) will be evaluated based on clinical chart review.

Trial Design

1Treatment groups

Experimental Treatment

Group I: EBUS-TBNAExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

EBUS-TBNA

2013

Completed Phase 4

~820

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,475 Previous Clinical Trials

484,940 Total Patients Enrolled

Kazuhiro Yasufuku, MDPrincipal InvestigatorUHN

3 Previous Clinical Trials

431 Total Patients Enrolled

Media Library

EBUS-TBNA (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT01786590 — N/A

Lung Cancer Research Study Groups: EBUS-TBNA

Lung Cancer Clinical Trial 2023: EBUS-TBNA Highlights & Side Effects. Trial Name: NCT01786590 — N/A

EBUS-TBNA (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01786590 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for patients to join the clinical trial?

"Affirmative. The clinicaltrial.gov database reveals that this trial, which was initially launched on February 1st 2021, is currently recruiting. Approximately 150 participants need to be sourced from a single site."

Answered by AI

What is the aggregate participation rate in this trial?

"Affirmative. Clinicaltrials.gov contains details confirming that this clinical trial is actively recruiting participants, beginning on February 1st 2013 and last updated on October 31st 2022. This experiment aims to enrol 150 volunteers from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)

2013. "Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01786590.

All > Lung > Sclc